as a novel treatment for obesity in combination with tirzepatide. STRIDES is being conducted in collaboration with Eli Lilly & Company's Chorus clinical development organization. Top-line results are ...

The FDA, however, warns that reports in a database aren’t yet verified and don’t mean the drugs have actually caused the harms reported.

The company received A+ for growth and profitability ... driven by strong revenue growth in its GLP-1 tirzepatide franchise - ...